The Official Addyi Coupon Program

Meet The Little Pink Pill

Addyi is the ONLY FDA-Approved little pink Pill!

Addyi was studied in over 2,000 women and is clinically proven to increase desire, increase the number of satisfying sexual events and decrease the distress associated with low libido.

Ready to See What Addyi Can Do For You?

”I’m back to my old self again! I can’t believe I’m saying that! THANK YOU!” – Lauren W.

Important Safety Information Including Boxed Warning and Indication

WARNING: HYPOTENSION AND SYNCOPE IN CERTAIN SETTINGS
See full prescribing information for complete boxed warning.

  • Use of ADDYI and alcohol together close in time increases the risk of severe hypotension and syncope. 

IMPORTANT SAFETY INFORMATION AND INDICATION

What is the most important information I should know about ADDYI?
Your risk of severe low blood pressure and fainting (loss of consciousness) is increased if you take ADDYI and:

  • drink alcohol close in time to when you take your ADDYI dose.
    • Wait at least 2 hours after drinking 1 or 2 standard alcoholic drinks before taking ADDYI at bedtime.
      Examples of 1 standard alcoholic drink include:
      one 12-ounce regular beer, 5 ounces of wine, 1.5 ounces of distilled spirits or shot
    • If you drink 3 or more standard alcoholic drinks in the evening, skip your ADDYI dose at bedtime.
    • After you have taken your ADDYI at bedtime, do not drink alcohol until the following day.
  • take certain prescription medicines, over-the-counter medicines, or herbal supplements. Do not take or start taking any prescription medicines, over-the-counter medicines, or herbal supplements while taking ADDYI until you have talked with your doctor. Your doctor will tell you if it is safe to take other medicines or herbal supplements while you are taking ADDYI.
  • have liver problems. Do not take ADDYI if you have liver problems.

If you take ADDYI and you feel lightheaded or dizzy, lie down right away. Get emergency medical help or ask someone to get emergency medical help for you if the symptoms do not go away or if you feel like you could faint (lose consciousness). If you faint (lose consciousness), tell your doctor as soon as you can.

Who should not take ADDYI?

Do not take ADDYI if you:

  • take certain medicines. Taking ADDYI with certain other medicines can increase the amount of ADDYI in your blood and cause severe low blood pressure, fainting (loss of consciousness), and sleepiness.
  • Do not take ADDYI if you are taking any of the following medicines:
    • Certain medicines used to treat HIV-1 infection
    • Certain medicines that you take by mouth used to treat fungal infections
    • Certain antibiotics
    • Certain medicines used to treat Hepatitis C infection
    • Certain medicines used to treat high blood pressure, chest pain (angina), or other heart problems
    • Nefazodone: a medicine used to treat depression

Ask your doctor or pharmacist if you are not sure if you take any of the medicines listed above. These are examples of the medicines that you should not take if you are taking ADDYI. Tell your doctor about all the medicines you take before you start taking ADDYI

  • have liver problems
  • are allergic to flibanserin or any of the ingredients in ADDYI. See Medication Guide for the full list of ingredients.

What should I tell my doctor before taking ADDYI?

Before you take ADDYI, tell your doctor about all of your medical conditions, including if you:

  • drink alcohol, use drugs, or have a history of alcohol or drug abuse
  • have ever had depression or other mental health problems
  • have low blood pressure or a medical condition that can cause low blood pressure
  • are pregnant or plan to become pregnant. It is not known if ADDYI will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if ADDYI passes into your breast milk. You and your doctor should decide if you will take ADDYI or breastfeed. You should not do both.

Tell your doctor if you have had an allergic reaction such as hives, itching, or trouble breathing during or after receiving a dose of ADDYI.

Tell your doctor about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. ADDYI can affect the way other medicines work, and other medicines can affect the way ADDYI works, and can cause serious side effects.

What should I avoid while taking ADDYI?

  • Do not drink alcohol close to the time you take your ADDYI dose because this increases your risk of severe low blood pressure and fainting (loss of consciousness).
  • Do not drive, operate machinery, or do things that require clear thinking until at least 6 hours after you take ADDYI and until you know how ADDYI affects you.
  • Do not drink grapefruit juice if you take ADDYI. Drinking grapefruit juice during your treatment with ADDYI increases your risk of severe low blood pressure and fainting (loss of consciousness).
  • You should not take the herbal supplements St. John’s Wort, ginkgo, or resveratrol or certain over-the-counter medicines such as cimetidine until you talk to your doctor. Taking ADDYI with these herbal supplements and over-the-counter medicines may increase your risk of low blood pressure, fainting (loss of consciousness), and sleepiness.

What are the possible side effects of ADDYI?

ADDYI can cause serious side effects, including:

  • Sleepiness is a common side effect of ADDYI and can be serious. Taking ADDYI can increase your risk of sleepiness if taken during waking hours, if you drink alcohol, or take certain medicines or herbal supplements.
  • Low blood pressure and fainting (loss of consciousness) can happen when you take ADDYI even if you do not drink alcohol or take other medicines or herbal supplements. Your risk of low blood pressure and fainting (loss of consciousness) is increased if ADDYI is taken during waking hours, if you drink alcohol within 2 hours of taking ADDYI, or if you take certain medicines or herbal supplements.

The most common side effects of ADDYI include:

  • Dizziness
  • Difficulty falling asleep or staying asleep
  • Nausea
  • Dry mouth
  • Tiredness

These are not all of the possible side effects of ADDYI. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

See full Prescribing Information, including BOXED WARNING regarding severe low blood pressure and fainting in certain settings, and Medication Guide at addyi.com/pi.

This information does not take the place of talking with your doctor.

INDICATION

What is ADDYI (add-ee) (flibanserin) Tablets?
ADDYI is a prescription medicine used to treat hypoactive (low) sexual desire disorder (HSDD) in women who have not gone through menopause, who have not had problems with low sexual desire in the past, and who have low sexual desire no matter the type of sexual activity, the situation, or the sexual partner. Women with HSDD have low sexual desire that is troubling to them. Their low sexual desire is not due to:

  • a medical or mental health problem
  • problems in the relationship
  • medicine or other drug use.

ADDYI is not for use for the treatment of HSDD in women who have gone through menopause, in men or in children.
ADDYI is not for use to enhance sexual performance.

PRIVACY POLICY | LEGAL NOTICE | TERMS & CONDITIONS

This site is intended for residents of the United States.
Addyi is a registered trademark of Sprout Pharmaceuticals, Inc. or its affiliates. All other trademarks are the property of their respective owners.
© 2024 Sprout Pharmaceuticals, Inc. US--2300154.02

sprout pharmaceuticals

References

1. IQVIA Monthly Total Prescriptions Volume Data Comparing Addyi vs Vyleesi in the US. August 2023 – September 2023
2. Addyi Prescribing Information.
3. Derogatis LR, Komer L, Katz M, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2012;9(4):1074-1085.
4. Thorp J, Simon J, Dattani D, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the DAISY study. J Sex Med. 2012;9(3):793-804.
5. Katz M, Derogatis LR, Ackerman R, et al. Treatment of hypoactive sexual desire disorder in premenopausal women: efficacy of flibanserin in the VIOLET Study. J Sex Med. 2013;10(7):1807-1815.
6. Gerstenberger EP, Rosen RC, Brewer JV, et al. Sexual desire and the Female Sexual Function Index (FSFI): a sexual desire cutpoint for clinical interpretation of the FSFI in women with and without hypoactive sexual desire disorder. J Sex Med. 2010;7(9):3096–3103.
7. Rosen R, Brown C, Heiman J, et al. The Female Sexual Function Index (FSFI): A multidimensional self-report instrument for the assessment of female sexual function. J Sex Marital Ther. 2006; 26:2, 191-208.
8. Simon JA, Millheiser L, Clayton AH, et al. Improvements in Female Sexual Function Index (FSFI) domains over time after flibanserin treatment in premenopausal women with hypoactive sexual desire disorder (HSDD). Poster presented at the International Society for the Study of Women’s Sexual Health (ISSWSH) 2020 Annual Meeting; March 5-8, 2020; Orlando, FL.(A084).
9. Kornstein SG, James JA, Apfel SC, et al. Effect of flibanserin treatment on body weight in premenopausal and postmenopausal women with hypoactive sexual desire disorder: A post hoc analysis. J Women’s Health. 2017;26(11):1161-1168. 
10. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers
11. Clayton AH, Harry AC, Yuan J, et al. Safety of flibanserin in women treated with antidepressants: A randomized, placebo-controlled study. J Sex Med 2018;15(1):43-51.
12. Stahl SM, et al. Mechanism of action of flibanserin, a multifunctional serotonin agonist and antagonist (MSAA), in hypoactive sexual desire disorder, CNS Spectrums. 2015;20:1-6.
13. Stevens DM, Weems JM, Brown L, et al. The pharmacodynamic effects of combined administration of flibanserin and alcohol. J Clin Pharm Ther. 2017; 42:598- 606.  https://doi.org/10.1111/jcpt.12563.
14. Simon JA, Clayton AH, Parish SJ, et al. Effects of alcohol administered with flibanserin in healthy premenopausal women: A randomized, double-blind, single-dose crossover study. J Sex Med. 2020;17:83-93. https://doi.org/10.1016/j.jsxm.2019.10.004
15. Simon JA, Clayton AH, Kingsberg SA, et al. Effects of timing of flibanserin administration relative to alcohol intake in healthy premenopausal women: A randomized, double-blind, crossover study. J Sex Med 2019;16:1779-1786. https://www.ncbi.nlm.nih.gov/pubmed/31522985
16. Millheiser L, Clayton AH, Parish SJ, et al. Safety and tolerability of evening ethanol consumption and bedtime administration of flibanserin in healthy premenopausal female subjects. Sex Med 2019;7:418-424. https://www.smoa.jsexmed.org/article/S2050-1161(19)30127-8/abstract
17. Arnow BA, Millheiser L, Garrett A et al. Women with hypoactive sexual desire disorder compared to normal females: a functional magnetic resonance imaging study. Neuroscience 2009;158:484-502.
18. Woodard TL, Nowak NT, Balon R et al. Brain activation patterns in women with acquired hypoactive sexual desire disorder and women with normal sexual function: a cross-sectional pilot study. Fertil Steril 2013;100:1068-1076.
19. Bianchi-Demicheli F, Cojan Y, Waber L, et al. Neural basis of hypoactive sexual desire disorder in women: an event-related fmri study.  J Sex Med. 2011;8:2546-2559.
20. Holstege G. How the emotional motor system controls the pelvic organs. Sex Med Rev. 2016: 4;303-328.
21. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed., Text Revision. Washington, DC: American Psychiatric Press; 2000.
22. Association of Reproductive Health Professionals. ARHP and Healthy Women (2009). Women’s Sexual Health Survey (online in the US). Harris Interactive.
23. Clayton AH, Goldfischer ER, Goldstein I,  et al. Validation of the Decreased Sexual Desire Screener (DSDS): a brief diagnostic instrument for generalized acquired female hypoactive sexual desire disorder (HSDD). J Sex Med. 2009;6(3):730-738.
24. Clayton AH, Brown L, Kim NN. Evaluation of safety for flibanserin. Expert Opin Drug Saf. 2020;19(1):1-8. doi:10.1080/14740338.2020.1707804
25. Goldfischer ER, Breaux J, Katz M et al. Continued efficacy and safety of flibanserin in premenopausal women with hypoactive sexual desire disorder (HSDD): Results from a randomized withdrawal trial. J Sex Med.2011; 8:3160-3172.
26. Jayne C, Simon JA, Taylor LV, Kimura T, Lesko LM; SUNFLOWER study investigators. Open-label extension study of flibanserin in women with hypoactive sexual desire disorder. J Sex Med. 2012;9(12):3180-3188. doi:10.1111/j.1743-6109.2012.02942.x